Glaucoma Drainage Devices (GDDs) Market By Product Type (Valved Glaucoma Drainage Devices, Non-Valved Glaucoma Drainage Devices, Adjustable Glaucoma Drainage Devices); By Application (Refractory Primary Open-Angle Glaucoma, Neovascular Glaucoma, Uveitic Glaucoma, Pediatric and Congenital Glaucoma, Other Secondary and Complex Glaucoma); By End User (Hospitals, Specialty Eye Hospitals and Clinics, Ambulatory Surgical Centers, Academic and Research Institutions); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Glaucoma Drainage Devices Market: Durable Pressure Control Is Expanding the Role of Tube Shunts

The Global Glaucoma Drainage Devices (GDDs) Market is valued at USD 991 million in 2025 and is projected to reach USD 1.73 billion by 2032, growing at a CAGR of 8.3%, according to Strategic Market Research.

 

The market covers permanent aqueous-shunt implants used during glaucoma surgery to lower intraocular pressure in eyes that are difficult to control through medication, laser treatment, or conventional filtering surgery. This analysis focuses on conventional tube-and-plate systems such as the Ahmed Glaucoma Valve, Ahmed ClearPath, Baerveldt implant, Molteno3, PAUL Glaucoma Implant, Aurolab Aqueous Drainage Implant, and adjustable systems such as eyeWatch. Trabecular micro-bypass MIGS implants and drug-delivery implants are excluded from the core category.

 

This distinction matters commercially because traditional drainage implants serve a narrower and more complex patient group than most MIGS products. GDDs are generally used in refractory, advanced, or secondary glaucoma when lower-risk treatment has failed, is unlikely to succeed, or cannot achieve the required pressure reduction. Their market value is therefore tied more closely to surgical conversion, surgeon preference, long-term outcomes, reimbursement, and specialist access than to total glaucoma prevalence. The segment shares, revenues, and growth rates below are based on Strategic Market Research estimates for the defined market.

 

Disease Burden Creates a Large Upstream Population

An estimated 4.22 million adults in the United States were living with glaucoma in 2022, including about 1.49 million with vision-affecting disease. Globally, approximately 76 million people aged 40–80 were estimated to have glaucoma in 2020, with the total projected to reach 111.8 million by 2040.

These figures define the upstream disease burden but not the commercial market for drainage implants. Most patients are managed with medication, laser treatment, or less invasive surgery and never progress to a conventional tube shunt. The addressable market narrows through diagnosis, inadequate pressure control, surgical eligibility, device selection, and implantation.

Vision-loss figures also indicate the seriousness of advanced disease. Glaucoma was associated with an estimated 3.61 million cases of blindness and about 4.14 million cases of moderate or severe vision impairment worldwide in 2020. This burden supports demand for durable pressure-lowering procedures, especially in patients whose optic nerve damage continues despite treatment.

 

Procedure Utilization Is the Best Measure of Demand

A Medicare analysis identified 221,602 glaucoma surgeries in the United States in 2021, compared with 80,151 in 2011. Within that total, 17,337 were glaucoma drainage implant procedures, representing about 7.8% of the procedures included in the analysis. The same period recorded a 58.5% decline in trabeculectomy procedures, showing how glaucoma surgery has diversified across drainage implants, MIGS, and cyclodestructive procedures. Not every displaced trabeculectomy converts into a tube-shunt procedure, but the trend supports a broader surgical role for GDDs in eyes where durable pressure control is required.

Procedure growth is influenced by aging, longer disease duration, more previously operated eyes, wider acceptance beyond rescue cases, bilateral disease, and repeat surgery.

 

Tube Shunts Are Moving Beyond a Rescue Role

Glaucoma drainage devices were historically used after medication, laser treatment, or trabeculectomy had failed. They continue to be most strongly associated with refractory disease, but surgeons increasingly consider them earlier in selected patients.

This shift is especially visible in advanced glaucoma, eyes with conjunctival scarring, inflammatory disease, previous retinal or corneal surgery, neovascular glaucoma, and cases in which a low target pressure is unlikely to be achieved through less invasive treatment. Some surgeons may also favor a drainage implant when medication adherence is poor or when the risk of filtration-surgery failure is high.

GDDs do not replace the broader glaucoma treatment pathway. Medication, selective laser trabeculoplasty, MIGS, trabeculectomy, and cyclophotocoagulation continue to compete for patients. The opportunity lies in the point at which a surgeon decides that a permanent drainage implant offers the most reliable balance of pressure reduction, complication risk, and long-term disease control.

 

Refractory Open-Angle Glaucoma Forms the Largest Clinical Segment

Refractory primary open-angle glaucoma is estimated to account for 58.6% of the 2025 market, equivalent to about USD 580.7 million. The segment is projected to expand at a CAGR of 7.9% through 2032, supported by the large underlying patient population and the need for stronger pressure control after medication, laser treatment, or prior surgery becomes inadequate.

Commercial conversion depends on diagnosis, adherence, progression, specialist access, target-pressure practices, and alternative procedures. Products competing in this segment must show durable pressure reduction, acceptable medication burden after surgery, manageable postoperative care, and low rates of tube exposure, corneal complications, hypotony, and reoperation.

Because these patients require prolonged treatment, long-term evidence carries more weight than short-term pressure reduction. Manufacturers with multi-year outcome data and strong surgeon familiarity are better positioned to defend market share.

 

Secondary and Pediatric Glaucoma Support High-Need Use

Secondary glaucoma, including neovascular, uveitic, aphakic, traumatic, and post-vitrectomy cases, is estimated to represent 34.1% of the market in 2025, or approximately USD 337.9 million. This segment is expected to grow at a CAGR of 9.1% through 2032, faster than refractory primary open-angle glaucoma, because these eyes frequently have inflammation, conjunctival scarring, altered anatomy, or previous surgery that makes conventional filtration less predictable.

GDDs are often selected because they create an alternative drainage pathway in eyes where tissue-related failure risk is high. Product choice depends on disease type, pressure target, anatomy, postoperative inflammation, and surgeon experience.

Pediatric and other less common indications account for the remaining 7.3%, equal to about USD 72.3 million in 2025. Childhood glaucoma is limited in volume but requires long-term durability and specialist care. Pediatric patients may undergo several procedures over a lifetime, creating demand for primary implantation, revision, repositioning, or replacement.

 

Valved Devices Compete on Early Pressure Control

Valved devices are estimated to hold 42.8% of the 2025 market, generating approximately USD 424.1 million. This segment is projected to grow at a CAGR of 7.6% through 2032. The category is closely associated with the Ahmed Glaucoma Valve, whose commercial position is supported by long-standing surgeon familiarity, multiple configurations, and use across adult and pediatric refractory glaucoma.

Valved designs restrict early aqueous flow and can reduce the risk of excessive drainage immediately after surgery. This may simplify early postoperative pressure management and make the device attractive in eyes where hypotony is a major concern.

 

Non-Valved Devices Compete on Lower Target Pressure

Non-valved devices are estimated to lead the product market with a 54.2% share in 2025, representing about USD 537.1 million. The segment is expected to expand at a CAGR of 8.7% through 2032. Baerveldt, Ahmed ClearPath, Molteno3, PAUL, and AADI products form the principal non-valved category and are generally positioned for stronger and more durable pressure reduction.

Temporary flow restriction is usually required during healing, which can increase surgical and postoperative complexity. However, non-valved devices may offer lower long-term pressure and reduced medication burden in patients with advanced or refractory disease.

Competition extends beyond plate size. Tube diameter, plate flexibility, implantation technique, tissue response, postoperative interventions, complication management, and surgeon training all influence adoption. AADI adds an affordability dimension, particularly in India and other price-sensitive markets where premium imported devices may limit access.

 

Adjustable Systems and Novel Materials Create New Differentiation

Adjustable and other emerging systems account for an estimated 3.0% of the 2025 market, or about USD 29.7 million, but are projected to record the fastest product-level CAGR of 12.1% through 2032.

Traditional drainage implants provide limited ability to change resistance after surgery without another procedure. Rheon Medical’s eyeWatch system is designed to be opened, closed, or set at intermediate positions after implantation. This could help clinicians address hypotony, inadequate drainage, or changing pressure targets without revision.

Developers are also investing in materials and plate designs intended to reduce fibrosis around the implant. Investigational products from W. L. Gore, Myra Vision, and Avisi Technologies are exploring biocompatible materials, pressure titration, lower-profile implants, and simplified implantation. Their commercial value will depend on whether they reduce revisions, medication use, corneal damage, postoperative visits, or long-term failure.

 

Competitive Landscape

New World Medical competes through the Ahmed Glaucoma Valve and Ahmed ClearPath portfolios, giving it exposure to both valved and non-valved segments. Johnson & Johnson Vision markets Baerveldt implants in different plate sizes and configurations, while Nova Eye Medical participates through Molteno3.

Advanced Ophthalmic Innovations markets the PAUL Glaucoma Implant internationally and has expanded its clinical evidence across refractory secondary glaucoma, childhood glaucoma, uveitic glaucoma, and post-vitrectomy cases. Rheon Medical competes through the adjustable eyeWatch and eyePlate system, while Aurolab addresses the affordability segment through AADI. Emerging developers include Myra Vision, Avisi Technologies, and W. L. Gore.

 

End-User and Regional Outlook

Hospitals and specialty eye centers are estimated to account for 69.4% of the 2025 market, equivalent to about USD 687.8 million. Their leadership reflects the concentration of advanced, secondary, pediatric, and previously operated glaucoma in specialist settings. Ambulatory surgery centers hold an estimated 24.8% share, or USD 245.8 million, and are projected to grow at a CAGR of 9.0% through 2032 as outpatient glaucoma surgery expands. Other settings account for 5.8%, or about USD 57.5 million.

North America leads the regional market with an estimated 38.6% share in 2025, equal to approximately USD 382.5 million. The region benefits from a large diagnosed population, experienced glaucoma specialists, established ambulatory surgery infrastructure, and stronger reimbursement access. It is projected to grow at a CAGR of 7.5% through 2032.

Europe accounts for about 27.4% of the market, or USD 271.5 million, and is expected to expand at an 8.0% CAGR. The region supports a wider mix of internationally available devices and serves as an early-adoption market for newer implants.

Asia-Pacific holds an estimated 25.8% share, representing about USD 255.7 million in 2025, and is projected to record the fastest regional CAGR of 9.6% through 2032. Developed markets support premium products and advanced clinical adoption, while India and other price-sensitive markets create demand for affordable implants, local manufacturing, and specialty eye-hospital distribution.

Latin America represents about 4.5% of the market, or USD 44.6 million, while the Middle East and Africa account for approximately 3.7%, or USD 36.7 million. Growth in these regions is linked to referral hospitals, private eye-care centers, public procurement, and charitable networks, although specialist shortages and limited reimbursement continue to restrict procedure access.

 

Market Drivers and Restraints

Growth is supported by aging populations, increasing numbers of advanced and previously operated eyes, declining reliance on trabeculectomy in some markets, and broader acceptance of tube shunts in selected high-risk patients.

The need for low and durable intraocular pressure also protects the role of GDDs against competition from less invasive procedures. MIGS products are often used in mild or moderate disease, while conventional drainage implants retain a stronger position in complex glaucoma requiring greater pressure reduction.

Only a small share of the total glaucoma population progresses to drainage-device surgery. Surgical and postoperative complexity also restrains adoption. Hypotony, tube exposure, corneal damage, blockage, retraction, diplopia, and revision surgery can increase the burden on patients and providers.

Competition remains intense across the treatment pathway. Medication, laser therapy, trabeculectomy, cyclophotocoagulation, MIGS, subconjunctival microstents, and sustained drug-delivery products may delay or prevent tube-shunt surgery. New products also face demanding evidence requirements because long-term ocular implants must demonstrate safety, durability, material stability, and consistent pressure-flow performance.

 

Market Opportunities and Outlook

The strongest opportunities lie in reducing the total burden of pressure management. Adjustable systems may reduce revision needs by allowing pressure changes after implantation. Novel materials may improve long-term performance by limiting fibrosis. Smaller tubes and plates may support use in anatomically difficult eyes, while affordable implants can widen access in emerging markets.

The projected increase from USD 991 million in 2025 to USD 1.73 billion by 2032 reflects a market being expanded by procedure conversion, product innovation, aging populations, and broader use in complex glaucoma. Commercial success will depend on measurable improvements in long-term failure, revision rates, corneal safety, postoperative visits, and total treatment cost.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 991 Million
Revenue Forecast in 2032	USD 1.73 Billion
Overall Growth Rate	CAGR of 8.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Valved Glaucoma Drainage Devices, Non-Valved Glaucoma Drainage Devices, Adjustable Glaucoma Drainage Devices
By Application	Refractory Primary Open-Angle Glaucoma, Neovascular Glaucoma, Uveitic Glaucoma, Pediatric and Congenital Glaucoma, Other Secondary and Complex Glaucoma
By End User	Hospitals, Specialty Eye Hospitals and Clinics, Ambulatory Surgical Centers, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, and South Africa
Market Drivers	Rising prevalence of refractory and complex glaucoma; growing need for long-term intraocular pressure control; wider adoption of drainage implants after unsuccessful conventional surgery; expansion of specialist ophthalmic surgical infrastructure
Customization Option	Available upon request